Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYPH - Cytoclonal Pharmaceutics -- Ignore unavailable to you. Want to Upgrade?

To: madman who wrote (113)	3/24/1998 9:11:00 AM
From: Labrador	Read Replies (1) \| Respond to of 428

I read the forbes article on Taxol. It seems that Bristol Myers has effectively tied up the market for Taxol, with exclusive extensions granted by the FDA. How can a competitor even touch this market with the FDA granting these additional arrangements to Bristol? And if a competitor (Immunex) tries to challenge it, it may take years. SO how can CYPH get a deal done unless they want to take what little Bristol grants them? With the FDA providing special treatment to Bristol, it seems that CYPH needs Bristol much more that Bristol needs CYPH -- Bristol thinks " let's keep the price high and the arrangements exclusive and make lots of $$$." So what can CYPH do -- and what can be its future?

To: madman who wrote (113)	5/6/1998 2:22:00 PM
From: Axxel	Respond to of 428

YEAH